News
Public · Published
Key facts: PALSONIFY added; povetacicept date set; CASGEVY revenue rises
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals, adding PALSONIFY to its portfolio and gaining a commercial presence in rare endocrine diseases. The FDA set a Nov. 30, 2026, action date for povetacicept in IgA nephropathy, and third-quarter CASGEVY revenue was $99 million.
Published:
Updated:
What happened
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals, adding PALSONIFY to its portfolio and gaining a commercial presence in rare endocrine diseases. The FDA set a Nov. 30, 2026, action date for povetacicept in IgA nephropathy, and third-quarter CASGEVY revenue was $99 million.
Confirmed
Global impact / market context
The acquisition adds a new product to Vertex's lineup and opens a commercial channel in rare endocrine diseases, which means new sales opportunities. The povetacicept action date gives investors a clear milestone, while CASGEVY revenue growth shows the gene therapy is gaining traction.
Analyst inference
Vertex guides 2026 revenue to $13.15 billion–$13.25 billion with $9.8 billion in cash available, which means it can fund launches, clinical trials, and deals like Crinetics. JOURNAVX prescription growth and the VX-017 plan in type 1 diabetes add longer-term drivers.
Analyst inference
What to watch
- The FDA action date for povetacicept in IgA nephropathy is Nov. 30, 2026, a regulatory decision point that could change the company's revenue outlook. Confirmed
- Vertex plans pivotal development of VX-017, its stem cell-derived islet therapy for type 1 diabetes, in 2027, a potential future growth driver if trials succeed. Proposed
- Watch whether CASGEVY revenue keeps growing after the 30% quarterly rise, since slower uptake would weaken the case for the gene therapy and its expansion into children. Analyst inference
Evidence
- Original source link unavailable